Steven R. Powell

Learn More
Multiple primary malignancies (MPMs) are increasing as cancer survivorship improves. A large analysis of the SEER database estimates that approximately 16 % of new cancers reported to their registry represent a second or higher order malignancy. The purpose of this study is to estimate the number of MPM diagnoses and to define differences in synchronous and(More)
AbstrAct Companies BLOCKINcan BLOCKINbenefit BLOCKINfrom BLOCKINdiversifying BLOCKINinter-nationally. This article analyzes the internation-alization efforts of six major European wireless telecommunications service providers: Telefonica, Deutsche Telekom, France Telecom, Vodafone, Telenor and TeliaSonera. Although all six companies have invested heavily in(More)
Background Immunotherapies have improved patient responses and survival , though not all patients benefit. Effective biomarkers may help to improve outcomes. Durvalumab is a human IgG1 mono-clonal antibody that inhibits PD-L1 binding to PD-1 and CD80, restoring antitumor immunity [1, 2]. PD-L1 expression on tumor or tumor-infiltrating immune cells measured(More)
ABStrAct In response to slowing growth, intensifying competition in their traditional wireless voice, text markets with an eye toward increasing revenues from offering a bundle of mobile and fixed-line voice, data, text, and video services to subscribers , management at Telefonica and America Movil have restructured their companies and reconsidered their(More)
  • 1